BioNTech closes three plants, founders exit; strategic pivot may unlock new growth

BioNTech is closing three production plants and its founders are stepping back, a significant restructuring after its COVID-era peak. The move signals a strategic pivot toward new therapeutic areas, but near-term costs and leadership transition create uncertainty. This matters as it could reshape the company's growth trajectory and investor sentiment.